flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

MDxHealth (R): SelectMDx Included in Dutch DRG Reimbursement System

MDxHealth SA ("MDxHealth, or the "Company"), (Euronext: MDXH.BR), a world leader in molecular diagnostics for urological cancers, today announced the inclusion of SelectMDx for Prostate Cancer, its non-invasive 'liquid biopsy' test that helps to identify patients at increased risk of having aggressive prostate cancer, in the Dutch Diagnosis Related Groups (DRG) reimbursement system.

Read more
20
Apr
2018

Galapagos creates new warrant plan

Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 1,585,000 warrants under new warrant plans for the benefit of employees, future employees, directors and a consultant of the company and its subsidiaries.

20
Apr
2018

VIB presents its 2017 annual results and confirms its reputation as global player

VIB is home to world-class researchers who are working across disciplines to tackle some of society’s major challenges. In eight thematic research centers, VIB creates opportunities for knowledge pooling which leads to inspiring collaborations between scientists within the centers and beyond. VIB’s proactive approach to technology transfer engages its researchers to convert their research results into concrete, marketable “products”.

20
Apr
2018

UgenTec Announces partnership with Serosep Ltd.

We're excited to announce today our partnership with Serosep Ltd., a leading global manufacturer of molecular solutions for clinical laboratories. In the partnership, we will add the Serosep EntericBio assay range to our platform FastFinder.

19
Apr
2018

Mithra Announces Positive Donesta® Phase IIb Study Achieving Primary Objective and Confirming Promising Safety Profile

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces positive topline results from the E4 Relief Phase II study of Donesta® for the treatment of Vasomotor Symptoms (VMS), and in particular hot flushes relief, in post-menopausal women, with the study achieving its primary and key secondary objectives. Donesta® is Mithra’s next-generation hormone therapy (HT) candidate with oral administration of Estetrol (E4).

20
Apr
2018

Galapagos creates new warrant plan

Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 1,585,000 warrants under new warrant plans for the benefit of employees, future employees, directors and a consultant of the company and its subsidiaries.

20
Apr
2018

VIB presents its 2017 annual results and confirms its reputation as global player

VIB is home to world-class researchers who are working across disciplines to tackle some of society’s major challenges. In eight thematic research centers, VIB creates opportunities for knowledge pooling which leads to inspiring collaborations between scientists within the centers and beyond. VIB’s proactive approach to technology transfer engages its researchers to convert their research results into concrete, marketable “products”.

20
Apr
2018

UgenTec Announces partnership with Serosep Ltd.

We're excited to announce today our partnership with Serosep Ltd., a leading global manufacturer of molecular solutions for clinical laboratories. In the partnership, we will add the Serosep EntericBio assay range to our platform FastFinder.

19
Apr
2018

Mithra Announces Positive Donesta® Phase IIb Study Achieving Primary Objective and Confirming Promising Safety Profile

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces positive topline results from the E4 Relief Phase II study of Donesta® for the treatment of Vasomotor Symptoms (VMS), and in particular hot flushes relief, in post-menopausal women, with the study achieving its primary and key secondary objectives. Donesta® is Mithra’s next-generation hormone therapy (HT) candidate with oral administration of Estetrol (E4).

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?